

# Kathrin Brockmann

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/5991988/kathrin-brockmann-publications-by-year.pdf>

**Version:** 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

73  
papers

2,668  
citations

24  
h-index

51  
g-index

79  
ext. papers

3,999  
ext. citations

6.6  
avg, IF

4.32  
L-index

#	Paper	IF	Citations
73	Dairy Intake and Parkinson's Disease: A Mendelian Randomization Study.. <i>Movement Disorders</i> , <b>2022</b> ,	7	2
72	Changes in CD163+, CD11b+, and CCR2+ peripheral monocytes relate to Parkinson's disease and cognition.. <i>Brain, Behavior, and Immunity</i> , <b>2022</b> , 101, 182-193	16.6	1
71	CSF and Serum Levels of Inflammatory Markers in PD: Sparse Correlation, Sex Differences and Association With Neurodegenerative Biomarkers.. <i>Frontiers in Neurology</i> , <b>2022</b> , 13, 834580	4.1	2
70	Blood and Cerebrospinal Fluid Biomarkers of Inflammation in Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , <b>2022</b> , 1-18	5.3	0
69	The longevity gene Klotho and its cerebrospinal fluid protein profiles as a modifier for Parkinson's disease. <i>European Journal of Neurology</i> , <b>2021</b> , 28, 1557-1565	6	2
68	Autonomic Symptoms in Older Adults Are Common and Associated With Health-Related Quality of Life. <i>Frontiers in Neurology</i> , <b>2021</b> , 12, 757748	4.1	0
67	Mendelian Randomisation Study of Smoking, Alcohol, and Coffee Drinking in Relation to Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , <b>2021</b> ,	5.3	3
66	Association between CSF alpha-synuclein seeding activity and genetic status in Parkinson's disease and dementia with Lewy bodies. <i>Acta Neuropathologica Communications</i> , <b>2021</b> , 9, 175	7.3	8
65	αSynuclein in Plasma-Derived Extracellular Vesicles Is a Potential Biomarker of Parkinson's Disease. <i>Movement Disorders</i> , <b>2021</b> , 36, 2508-2518	7	3
64	Investigation of Autosomal Genetic Sex Differences in Parkinson's Disease. <i>Annals of Neurology</i> , <b>2021</b> , 90, 35-42	9.4	6
63	Genomewide Association Studies of LRRK2 Modifiers of Parkinson's Disease. <i>Annals of Neurology</i> , <b>2021</b> , 90, 76-88	9.4	9
62	Identification of sixteen novel candidate genes for late onset Parkinson's disease. <i>Molecular Neurodegeneration</i> , <b>2021</b> , 16, 35	19	3
61	CSF Protein Level of Neurotransmitter Secretion, Synaptic Plasticity, and Autophagy in PD and DLB. <i>Movement Disorders</i> , <b>2021</b> , 36, 2595-2604	7	4
60	Gut Microbiome Signatures of Risk and Prodromal Markers of Parkinson Disease. <i>Annals of Neurology</i> , <b>2021</b> , 90, E1-E12	9.4	7
59	Soluble CD163 Changes Indicate Monocyte Association With Cognitive Deficits in Parkinson's Disease. <i>Movement Disorders</i> , <b>2021</b> , 36, 963-976	7	11
58	Phenylalanine Effects on Brain Function in Adult Phenylketonuria. <i>Neurology</i> , <b>2021</b> , 96, e399-e411	6.5	8
57	Analysis of DNM3 and VAMP4 as genetic modifiers of LRRK2 Parkinson's disease. <i>Neurobiology of Aging</i> , <b>2021</b> , 97, 148.e17-148.e24	5.6	9

56	The Mutation Matters: CSF Profiles of GCase, Sphingolipids, ESynuclein in PD. <i>Movement Disorders</i> , <b>2021</b> , 36, 1216-1228	7	12
55	Abnormally reduced frontal cortex activity during Trail-Making-Test in prodromal parkinson's disease-a fNIRS study. <i>Neurobiology of Aging</i> , <b>2021</b> , 105, 148-158	5.6	1
54	Finding genetically-supported drug targets for Parkinson's disease using Mendelian randomization of the druggable genome.. <i>Nature Communications</i> , <b>2021</b> , 12, 7342	17.4	2
53	-Associated Synucleinopathies: Prime Candidates for Alpha-Synuclein Targeting Compounds. <i>Frontiers in Cell and Developmental Biology</i> , <b>2020</b> , 8, 562522	5.7	2
52	Penetrance of Parkinson's Disease in LRRK2 p.G2019S Carriers Is Modified by a Polygenic Risk Score. <i>Movement Disorders</i> , <b>2020</b> , 35, 774-780	7	27
51	Intraindividual Neurofilament Dynamics in Serum Mark the Conversion to Sporadic Parkinson's Disease. <i>Movement Disorders</i> , <b>2020</b> , 35, 1233-1238	7	10
50	Parkinson's Disease: Glucocerebrosidase 1 Mutation Severity Is Associated with CSF Alpha-Synuclein Profiles. <i>Movement Disorders</i> , <b>2020</b> , 35, 495-499	7	22
49	Genetic modifiers of risk and age at onset in GBA associated Parkinson's disease and Lewy body dementia. <i>Brain</i> , <b>2020</b> , 143, 234-248	11.2	69
48	Insulin sensitivity predicts cognitive decline in individuals with prediabetes. <i>BMJ Open Diabetes Research and Care</i> , <b>2020</b> , 8,	4.5	13
47	CSF NFL in a Longitudinally Assessed PD Cohort: Age Effects and Cognitive Trajectories. <i>Movement Disorders</i> , <b>2020</b> , 35, 1138-1144	7	10
46	The endocytic membrane trafficking pathway plays a major role in the risk of Parkinson's disease. <i>Movement Disorders</i> , <b>2019</b> , 34, 460-468	7	40
45	Dementia with lewy bodies: GBA1 mutations are associated with cerebrospinal fluid alpha-synuclein profile. <i>Movement Disorders</i> , <b>2019</b> , 34, 1069-1073	7	18
44	Gait analysis with wearables predicts conversion to parkinson disease. <i>Annals of Neurology</i> , <b>2019</b> , 86, 357-367	9.4	57
43	Identification of novel risk loci, causal insights, and heritable risk for Parkinson's disease: a meta-analysis of genome-wide association studies. <i>Lancet Neurology</i> , <i>The</i> , <b>2019</b> , 18, 1091-1102	24.1	562
42	Parkinson's disease: evolution of cognitive impairment and CSF Aβ profiles in a prospective longitudinal study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , <b>2019</b> , 90, 165-170	5.5	7
41	Effect of physical activity on cognitive flexibility, depression and RBD in healthy elderly. <i>Clinical Neurology and Neurosurgery</i> , <b>2018</b> , 165, 88-93	2	17
40	Biallelic Parkin (PARK2) mutations can cause a bvFTD phenotype without clinically relevant parkinsonism. <i>Parkinsonism and Related Disorders</i> , <b>2018</b> , 55, 145-147	3.6	4
39	Serum neurofilament light is increased in multiple system atrophy of cerebellar type and in repeat-expansion spinocerebellar ataxias: a pilot study. <i>Journal of Neurology</i> , <b>2018</b> , 265, 1618-1624	5.5	36

38	Polygenic load: Earlier disease onset but similar longitudinal progression in Parkinson's disease. <i>Movement Disorders</i> , <b>2018</b> , 33, 1349-1353	7	7
37	Arm swing asymmetry in overground walking. <i>Scientific Reports</i> , <b>2018</b> , 8, 12803	4.9	11
36	Assessment von Alltagsfunktionen und Therapie bei Parkinson-Demenz. <i>Neurotransmitter</i> , <b>2018</b> , 29, 34-43	0.1	1
35	Dermal Phospho-Alpha-Synuclein Deposition in Patients With Parkinson's Disease and Mutation of the Glucocerebrosidase Gene. <i>Frontiers in Neurology</i> , <b>2018</b> , 9, 1094	4.1	10
34	Deterioration of executive dysfunction in elderly with REM sleep behavior disorder (RBD). <i>Neurobiology of Aging</i> , <b>2018</b> , 70, 242-246	5.6	9
33	Application of the movement disorder society prodromal Parkinson's disease research criteria in 2 independent prospective cohorts. <i>Movement Disorders</i> , <b>2017</b> , 32, 1025-1034	7	53
32	Cognitive impairment in Glucocerebrosidase (GBA)-associated PD: Not primarily associated with cerebrospinal fluid Abeta and Tau profiles. <i>Movement Disorders</i> , <b>2017</b> , 32, 1780-1783	7	17
31	Cognitive changes in prodromal Parkinson's disease: A review. <i>Movement Disorders</i> , <b>2017</b> , 32, 1655-16667		53
30	Dual-Task Performance in GBA Parkinson's Disease. <i>Parkinsons Disease</i> , <b>2017</b> , 2017, 8582740	2.6	1
29	Distinct metabolomic signature in cerebrospinal fluid in early parkinson's disease. <i>Movement Disorders</i> , <b>2017</b> , 32, 1401-1408	7	53
28	Metformin reverses TRAP1 mutation-associated alterations in mitochondrial function in Parkinson's disease. <i>Brain</i> , <b>2017</b> , 140, 2444-2459	11.2	59
27	SNPs in A $\beta$ clearance proteins: Lower CSF A $\beta$ levels and earlier onset of dementia in PD. <i>Neurology</i> , <b>2017</b> , 89, 2335-2340	6.5	10
26	Penetrance estimate of LRRK2 p.G2019S mutation in individuals of non-Ashkenazi Jewish ancestry. <i>Movement Disorders</i> , <b>2017</b> , 32, 1432-1438	7	74
25	Excessive burden of lysosomal storage disorder gene variants in Parkinson's disease. <i>Brain</i> , <b>2017</b> , 140, 3191-3203	11.2	209
24	Arm swing as a potential new prodromal marker of Parkinson's disease. <i>Movement Disorders</i> , <b>2016</b> , 31, 1527-1534	7	80
23	Prospective longitudinal course of cognition in older subjects with mild parkinsonian signs. <i>Alzheimers Research and Therapy</i> , <b>2016</b> , 8, 42	9	10
22	Inflammatory profile in LRRK2-associated prodromal and clinical PD. <i>Journal of Neuroinflammation</i> , <b>2016</b> , 13, 122	10.1	33
21	Broad clinical phenotype in Parkinsonism associated with a base pair deletion in RAB39B and additional POLG variant. <i>Parkinsonism and Related Disorders</i> , <b>2016</b> , 31, 148-150	3.6	14

20	Reasons for mild parkinsonian signs - which constellation may indicate neurodegeneration?. <i>Parkinsonism and Related Disorders</i> , <b>2015</b> , 21, 126-30	3.6	14
19	Clinical characteristics related to worsening of motor function assessed by the Unified Parkinson's Disease Rating Scale in the elderly population. <i>Journal of Neurology</i> , <b>2015</b> , 262, 451-8	5.5	4
18	Neurodegenerative CSF markers in genetic and sporadic PD: Classification and prediction in a longitudinal study. <i>Parkinsonism and Related Disorders</i> , <b>2015</b> , 21, 1427-34	3.6	16
17	EIF4G1 is neither a strong nor a common risk factor for Parkinson's disease: evidence from large European cohorts. <i>Journal of Medical Genetics</i> , <b>2015</b> , 52, 37-41	5.8	15
16	Association between vestibulo-ocular reflex suppression, balance, gait, and fall risk in ageing and neurodegenerative disease: protocol of a one-year prospective follow-up study. <i>BMC Neurology</i> , <b>2015</b> , 15, 192	3.1	11
15	GBA-associated Parkinson's disease: reduced survival and more rapid progression in a prospective longitudinal study. <i>Movement Disorders</i> , <b>2015</b> , 30, 407-11	7	135
14	Age and Vascular Burden Determinants of Cortical Hemodynamics Underlying Verbal Fluency. <i>PLoS ONE</i> , <b>2015</b> , 10, e0138863	3.7	17
13	The significance of GBA for Parkinson's disease. <i>Journal of Inherited Metabolic Disease</i> , <b>2014</b> , 37, 643-8	5.4	26
12	A neurodegenerative vascular burden index and the impact on cognition. <i>Frontiers in Aging Neuroscience</i> , <b>2014</b> , 6, 161	5.3	13
11	Mild parkinsonian signs in the elderly--is there an association with PD? Cross-sectional findings in 992 individuals. <i>PLoS ONE</i> , <b>2014</b> , 9, e92878	3.7	21
10	Leucine-rich repeat kinase 2 functionally interacts with microtubules and kinase-dependently modulates cell migration. <i>Neurobiology of Disease</i> , <b>2013</b> , 54, 280-8	7.5	47
9	SNCA: major genetic modifier of age at onset of Parkinson's disease. <i>Movement Disorders</i> , <b>2013</b> , 28, 1217-21	7	28
8	A pathway-based analysis provides additional support for an immune-related genetic susceptibility to Parkinson's disease. <i>Human Molecular Genetics</i> , <b>2013</b> , 22, 1039-49	5.6	96
7	Enlarged hyperechogenic substantia nigra as a risk marker for Parkinson's disease. <i>Movement Disorders</i> , <b>2013</b> , 28, 216-9	7	90
6	A multicenter study of glucocerebrosidase mutations in dementia with Lewy bodies. <i>JAMA Neurology</i> , <b>2013</b> , 70, 727-35	17.2	285
5	GBA-associated PD. Neurodegeneration, altered membrane metabolism, and lack of energy failure. <i>Neurology</i> , <b>2012</b> , 79, 213-20	6.5	36
4	Poor trail making test performance is directly associated with altered dual task prioritization in the elderly--baseline results from the TREND study. <i>PLoS ONE</i> , <b>2011</b> , 6, e27831	3.7	58
3	Clinical and brain imaging characteristics in leucine-rich repeat kinase 2-associated PD and asymptomatic mutation carriers. <i>Movement Disorders</i> , <b>2011</b> , 26, 2335-42	7	55

2 TCS in monogenic forms of Parkinson's disease. *International Review of Neurobiology*, **2010**, 90, 157-64 4.4 9

1 GBA-associated PD: chances and obstacles for targeted treatment strategies. *Journal of Neural Transmission*, 4.3 0